Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies

Kenney, John S.; Hughes, Brian; Masada, Marvin P.; Allison, A. C.

doi:10.1016/0022-1759(89)90156-7

Cited by 200 publications

(88 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The SC injection route may also target these specific Agn presenting cells. These results are in agreement with Kenney et al [56], who observed enhanced Ab titers when using SC injections compared to IP. However, other groups have reported the opposite effect [57,58], suggesting that route requires optimization for each unique Agn and Adj combination.…”

Section: Phage As a Carrier For The B21 Synthetic Peptidesupporting

confidence: 93%

Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide

Houten

Zwick

Menéndez

et al. 2006

Vaccine

View full text Add to dashboard Cite

Filamentous bacteriophage are widely used as immunogenic carriers for "phage-displayed" recombinant peptides. Here we report that they are an effective immunogenic carrier for synthetic peptides. The f1.K phage was engineered to have an additional Lys residue near the N-terminus of the major coat protein, pVIII, so as to enhance access to chemical cross-linking agents. The dimeric synthetic peptide, B2

show abstract

Section: Phage As a Carrier For The B21 Synthetic Peptidesupporting

confidence: 93%

Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide

Houten

Zwick

Menéndez

et al. 2006

Vaccine

View full text Add to dashboard Cite

show abstract

“…Meningococcal LPS as an adjuvant increased IgG2a in mice by 7.3-fold (Table 1). In mice, IgG2a is a protective isotype due to its ability to fix complement and induce antibodydependent cell-mediated cytotoxicity by macrophages [38,39]. Bactericidal activity is a vital correlate of protection against meningococcal disease.…”

Section: Discussionmentioning

confidence: 99%

TLR4-dependent adjuvant activity of Neisseria meningitidis lipid A

Zughaier

Steeghs

Ley³

et al. 2007

Vaccine

View full text Add to dashboard Cite

The adjuvant activity of Neisseria meningitidis serogroup B lipopoly(oligo)saccharide (LOS) from wild-type and genetically-defined LOS mutants and unglycosylated meningococcal lipid A was assessed in C3H/HeN and C3H/HeJ mice. Meningococcal lipid A, a weak agonist for TLR4/MD-2 in human macrophages, was found to have adjuvant activity similar to that of wild-type and KDO 2 -lipid A LOS in C3H/HeN mice. All meningococcal LOS structures as adjuvants induced high titers of IgG1, IgG2a and IgG2b but very little IgG3 to OMP compared to no adjuvant PBS controls. In addition, induced OMP antibodies were shown to have high bactericidal activity against serogroup B meningococci. Purified LOS and lipid A structures failed to induce any adjuvant activity in C3H/ HeJ mice indicating that meningococcal LOS as an adjuvant was TLR4-dependent. Unglycosylated meningococcal lipid A because of its weak agonist activity for human macrophages and retention of adjuvant activity may be a candidate for use in serogroup B meningococcal OMP and OMV vaccines and for use as an adjuvant in other vaccines.

show abstract

“…The limitations of alum are a driving force for research into new adjuvant systems. The characterization of aluminum salt adjuvants as Th2-directing systems that stimulate IgE production and very poor cellular immunity is well documented [196,197]. Thus, alum alone is inappropriate for use against a variety of diseases that require Th1/cellular immune responses.…”

Section: Historical Progressionmentioning

confidence: 99%